Savitz Ryan reported option exercise involving 10,399 derivative units of Dianthus Therapeutics, Inc. DE at $0.00 for $0 on Nov 9, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
EVP, CFO & CBO
EVP, CFO & CBO
Filed Nov 12, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
10,399Stock Option (Right to Buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
0Direct
Trade date
Nov 9, 2026Option exercise
Filed
Nov 12, 2026, 5:32 PM ET3-day reporting delay
Accession
0001992324-26-000010Code M · Transaction 399558
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Related trades are temporarily unavailable. Open the SEC filing for the complete report, or reload this page.

DNTH price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
DNTH · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 19, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago +0.1%1w ago 0%1d ago 0%
Returns since7d30d90d180d1y

Footnotes in full

F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2026. F2: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.09 to $85.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F3: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.36 to $87.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F4: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.21 to $89.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F5: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.44 to $90.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F6: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $90.44 to $91.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F7: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.46 to $92.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F8: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $90.00 to $90.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F9: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $90.00 to $90.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F10: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $90.00 to $90.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F11: The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date. F12: The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after May 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date. F13: The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date. F14: The shares of common stock underlying this stock option award vested as to 25% of the shares on June 2, 2023, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.